BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 16314544)

  • 1. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
    Ballantyne CM; Hoogeveen RC; Bang H; Coresh J; Folsom AR; Chambless LE; Myerson M; Wu KK; Sharrett AR; Boerwinkle E
    Arch Intern Med; 2005 Nov; 165(21):2479-84. PubMed ID: 16314544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
    Ballantyne CM; Hoogeveen RC; Bang H; Coresh J; Folsom AR; Heiss G; Sharrett AR
    Circulation; 2004 Feb; 109(7):837-42. PubMed ID: 14757686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany.
    Koenig W; Khuseyinova N; Löwel H; Trischler G; Meisinger C
    Circulation; 2004 Oct; 110(14):1903-8. PubMed ID: 15451783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke.
    Elkind MS; Tai W; Coates K; Paik MC; Sacco RL
    Arch Intern Med; 2006 Oct; 166(19):2073-80. PubMed ID: 17060536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study.
    Nambi V; Hoogeveen RC; Chambless L; Hu Y; Bang H; Coresh J; Ni H; Boerwinkle E; Mosley T; Sharrett R; Folsom AR; Ballantyne CM
    Stroke; 2009 Feb; 40(2):376-81. PubMed ID: 19095974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein-associated phospholipase A2, hormone use, and the risk of ischemic stroke in postmenopausal women.
    Wassertheil-Smoller S; Kooperberg C; McGinn AP; Kaplan RC; Hsia J; Hendrix SL; Manson JE; Berger JS; Kuller LH; Allison MA; Baird AE
    Hypertension; 2008 Apr; 51(4):1115-22. PubMed ID: 18259035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relation of markers of inflammation (C-reactive protein, white blood cell count, and lipoprotein-associated phospholipase A2) to the ankle-brachial index.
    Santos S; Rooke TW; Bailey KR; McConnell JP; Kullo IJ
    Vasc Med; 2004 May; 9(3):171-6. PubMed ID: 15675180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study.
    Oei HH; van der Meer IM; Hofman A; Koudstaal PJ; Stijnen T; Breteler MM; Witteman JC
    Circulation; 2005 Feb; 111(5):570-5. PubMed ID: 15699277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
    Charniot JC; Khani-Bittar R; Albertini JP; Giral P; Cherfils C; Cosson C; Guillerm E; Leprince P; Gandjbakhch I; Bonnefont-Rousselot D
    Int J Cardiol; 2013 Sep; 168(1):132-8. PubMed ID: 23103135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of lipoprotein-associated phospholipase A
    Han L; Zhong C; Bu X; Xu T; Wang A; Peng Y; Xu T; Wang J; Peng H; Li Q; Ju Z; Geng D; Zhang Y; He J;
    Atherosclerosis; 2017 Nov; 266():1-7. PubMed ID: 28934604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein-associated phospholipase A2 is associated with risk of dementia.
    van Oijen M; van der Meer IM; Hofman A; Witteman JC; Koudstaal PJ; Breteler MM
    Ann Neurol; 2006 Jan; 59(1):139-44. PubMed ID: 16278861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up.
    Brilakis ES; McConnell JP; Lennon RJ; Elesber AA; Meyer JG; Berger PB
    Eur Heart J; 2005 Jan; 26(2):137-44. PubMed ID: 15618069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis.
    Zhang J; Xu DL; Liu XB; Bi SJ; Zhao T; Sui SJ; Ji XP; Lu QH
    Yonsei Med J; 2016 Mar; 57(2):321-7. PubMed ID: 26847282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.
    Kiechl S; Willeit J; Mayr M; Viehweider B; Oberhollenzer M; Kronenberg F; Wiedermann CJ; Oberthaler S; Xu Q; Witztum JL; Tsimikas S
    Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1788-95. PubMed ID: 17541022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community.
    Gerber Y; McConnell JP; Jaffe AS; Weston SA; Killian JM; Roger VL
    Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2517-22. PubMed ID: 16902161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.
    O'Donoghue M; Morrow DA; Sabatine MS; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    Circulation; 2006 Apr; 113(14):1745-52. PubMed ID: 16537575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe periodontitis is associated with the serum levels of hypersensitive C reactive protein and lipoprotein-associated phospholipase A2 in the patients of acute ischemic stroke.
    Chen C; Zhu J; Deng X; Yang Z; Lin W; Ma Y; Huang S; Chen L; Liu Y; Zhu F
    J Clin Neurosci; 2021 Jun; 88():232-236. PubMed ID: 33992190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
    Sabatine MS; Morrow DA; O'Donoghue M; Jablonksi KA; Rice MM; Solomon S; Rosenberg Y; Domanski MJ; Hsia J;
    Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2463-9. PubMed ID: 17766330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus.
    Wootton PT; Stephens JW; Hurel SJ; Durand H; Cooper J; Ninio E; Humphries SE; Talmud PJ
    Atherosclerosis; 2006 Nov; 189(1):149-56. PubMed ID: 16438975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of statin therapy on lipoprotein associated phospholipase A2 levels.
    Albert MA; Glynn RJ; Wolfert RL; Ridker PM
    Atherosclerosis; 2005 Sep; 182(1):193-8. PubMed ID: 15982658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.